Anesthesiology Research Analysis
March 2026 anesthesiology research converged on precision critical care, AI-enabled neuromonitoring, and safer analgesia. Biomarker-guided strategies advanced at both the diagnostic and therapeutic levels, including a validated three-biomarker immune-dysregulation framework and a Bayesian phase 3 trial suggesting mortality benefit from polymyxin B hemoadsorption in endotoxic septic shock. Adversarial AI provided cross-species mechanistic signatures of consciousness and identified subthalamic nuc
Summary
March 2026 anesthesiology research converged on precision critical care, AI-enabled neuromonitoring, and safer analgesia. Biomarker-guided strategies advanced at both the diagnostic and therapeutic levels, including a validated three-biomarker immune-dysregulation framework and a Bayesian phase 3 trial suggesting mortality benefit from polymyxin B hemoadsorption in endotoxic septic shock. Adversarial AI provided cross-species mechanistic signatures of consciousness and identified subthalamic nucleus stimulation as a candidate intervention, while a Phase 4 trial of the biased μ-agonist oliceridine reduced hypoxia during ambulatory sedation. Complementary translational work on Drp1-dependent tunneling nanotubes in septic myocardium highlighted organ-protection pathways ready for future clinical exploration.
Selected Articles
1. Polymyxin B haemoadsorption in endotoxic septic shock (Tigris): a multicentre, open-label, Bayesian, randomised, controlled, phase 3 trial.
A biomarker-enriched Bayesian phase 3 trial (n=157) in vasopressor-dependent septic shock with high endotoxin activity showed a high posterior probability of reduced 28- and 90-day mortality with two sessions of polymyxin B hemoadsorption added to standard care, with acceptable safety.
Impact: Delivers prospective randomized evidence that a biomarker-targeted extracorporeal therapy can improve survival signals in a rigorously phenotyped septic shock subgroup, advancing precision critical care.
Clinical Implications: Consider polymyxin B hemoadsorption as an adjunct in centers with capability for adults with endotoxin activity 0.60–0.89 and multiorgan dysfunction, with strict selection, monitoring, and auditing while awaiting larger pragmatic confirmation.
Key Findings
- Biomarker-enriched enrollment (endotoxin activity 0.60–0.89) in vasopressor-dependent septic shock (n=157).
- High posterior probabilities of benefit at 28 and 90 days; adjusted 90-day OR 0.54 (95% CrI 0.32–0.87).
- Acceptable safety profile with two treatment-related serious adverse events.
2. Adversarial AI reveals mechanisms and treatments for disorders of consciousness.
A generative adversarial AI trained on >680,000 neuroelectrophysiology samples reproduced cross-species signatures of consciousness and coma, predicted mechanistic pathways (e.g., basal ganglia indirect pathway disruption, enhanced cortical inhibitory-to-inhibitory coupling), and highlighted subthalamic nucleus stimulation as a candidate therapy.
Impact: Bridges large-scale neuroscience with anesthesiology and critical care by producing testable, causal hypotheses and neuromodulation targets for disorders of consciousness.
Clinical Implications: Guides development of mechanistic biomarkers and neuromodulation trials (e.g., subthalamic nucleus stimulation) and informs refinement of perioperative consciousness monitoring.
Key Findings
- Cross-species modeling of consciousness/coma using >680,000 10-s segments with validation in 565 humans/animals.
- Predicted basal ganglia indirect pathway disruption and increased cortical inhibitory-to-inhibitory coupling, supported by diffusion MRI and RNA-seq/animal data.
- Identified subthalamic nucleus high-frequency stimulation as a promising therapeutic target.
3. Effect of oliceridine on hypoxia during sedated hysteroscopy: a Phase 4 randomized clinical trial.
In 492 patients undergoing sedated hysteroscopy, the G protein–biased μ-agonist oliceridine halved intraoperative hypoxia versus sufentanil and improved nadir SpO2 and propofol requirements, demonstrating enhanced respiratory safety in ambulatory sedation.
Impact: Provides large, pragmatic randomized evidence that biased μ-agonism can reduce hypoxia during procedural sedation, directly informing opioid choice for safer ambulatory anesthesia.
Clinical Implications: Oliceridine may be considered in ambulatory gynecologic sedation protocols to reduce hypoxia risk, with attention to availability, monitoring, and cost-impact within ERAS pathways.
Key Findings
- Randomized, double-blind comparison of oliceridine vs sufentanil during sedated hysteroscopy (n=492).
- Hypoxia: 9.8% with oliceridine vs 19.5% with sufentanil (RR 0.50; 95% CI 0.32–0.79; P=0.002).
- Higher nadir SpO2 and reduced supplemental propofol in the oliceridine group.
4. Quantifying immune dysregulation in pneumonia and sepsis with a parsimonious machine-learning model: a multicohort analysis across care settings and reanalysis of a hydrocortisone randomised controlled trial.
A validated three-biomarker ML framework (procalcitonin, sTREM-1, IL-6) quantified immune dysregulation (DIP/cDIP), linked higher dysregulation to mortality and secondary infection, and identified hydrocortisone benefit restricted to severely dysregulated patients in post-hoc RCT reanalysis.
Impact: Enables biomarker-guided immunomodulation by resolving sepsis heterogeneity with a simple, deployable tool—potentially redefining steroid allocation.
Clinical Implications: Measure PCT, sTREM-1, and IL-6 to stratify pneumonia/sepsis patients for corticosteroids and to design enriched, biomarker-stratified trials.
Key Findings
- Three-biomarker model predicted immune dysregulation with high accuracy (DIP 91.2%, cDIP RMSE 0.056).
- Higher cDIP independently associated with mortality and secondary infection.
- Hydrocortisone benefit confined to severely dysregulated patients (e.g., cDIP ≥0.63).
5. Cytoskeletal remodeling promotes tunneling nanotube formation and drives cardiac resident cell mitochondrial transfer in sepsis.
A mechanistic study in septic myocardium shows Drp1-driven cytoskeletal remodeling orchestrates tunneling nanotube biogenesis and intercellular mitochondrial trafficking; cardiac Drp1 knockout disrupts this exchange and halts metabolic deterioration, nominating Drp1/TNT as a therapeutic axis.
Impact: Reveals a nanoscale organelle-transfer mechanism linking cytoskeletal dynamics to cardiac metabolic failure in sepsis, offering tractable translational targets.
Clinical Implications: Suggests Drp1/TNT modulation as a novel strategy to prevent or mitigate septic cardiomyopathy; next steps include human tissue validation and pharmacologic modulation.
Key Findings
- Drp1-driven cytoskeletal remodeling governs TNT biogenesis and mitochondrial trafficking.
- Cardiac Drp1 knockout disrupts TNT-mediated exchange and halts metabolic deterioration.
- Single-cell omics and CLP models provided convergent mechanistic evidence.